AC Immune (NASDAQ:ACIU) Earns Buy Rating from BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research’s price objective points to a potential upside of 193.90% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on ACIU. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a research report on Monday, August 24th. Weiss Ratings restated a “sell (e+)” rating on shares of AC Immune in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, AC Immune currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

AC Immune Trading Down 3.8%

ACIU opened at $2.72 on Wednesday. AC Immune has a twelve month low of $2.10 and a twelve month high of $4.00. The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11. The company has a fifty day moving average of $2.55 and a 200-day moving average of $2.68. The stock has a market cap of $277.02 million, a PE ratio of -5.11 and a beta of 1.60.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The company had revenue of $18.67 million during the quarter, compared to analysts’ expectations of $9.59 million. On average, sell-side analysts predict that AC Immune will post -0.6 EPS for the current year.

Hedge Funds Weigh In On AC Immune

Institutional investors have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership raised its holdings in shares of AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after purchasing an additional 30,035 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the period. Finally, AXQ Capital LP acquired a new position in shares of AC Immune during the second quarter valued at about $25,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

Key AC Immune News

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Positive Phase 2 results support the platform. In Part 1 of the VacSYn Phase 2 trial, ACI-7104 met all primary safety and immunogenicity endpoints through week 100. The company reported that the treatment was generally safe and well tolerated, produced a 100% antibody response after three immunizations, showed antibody penetration into cerebrospinal fluid, and generated signals of target engagement. AC Immune Reports Positive Safety and Immunogenicity at Week 100
• Positive Sentiment: Analysts maintained bullish views and high price targets. BTIG Research reaffirmed its Buy rating and assigned an $8.00 target, while H.C. Wainwright analyst Andrew Fein maintained a Buy rating and a $12.00 target. The targets imply substantial potential upside if ACI-7104 advances successfully through development. BTIG Reaffirms Buy Rating on AC Immune H.C. Wainwright Maintains Buy Rating and Price Target
• Neutral Sentiment: Important development milestones remain ahead. Part 1 primarily evaluated safety and immune response; Part 2 is intended to provide evidence of clinical activity and inform a potential Phase 3 decision. AC Immune expects to discuss the future development path with the FDA in early 2027, so clinical efficacy and regulatory risk remain unresolved.

AC Immune Company Profile

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.